O	0	9	Chemokine	Chemokine	NN	B-NP
O	10	18	receptor	receptor	NN	I-NP
O	19	24	CXCR4	CXCR4	NN	I-NP
O	25	35	expression	expression	NN	I-NP
O	35	36	,	,	,	O
O	37	45	function	function	NN	B-NP
O	45	46	,	,	,	O
O	47	50	and	and	CC	O
O	51	59	clinical	clinical	JJ	B-NP
O	60	72	implications	implication	NNS	I-NP
O	73	75	in	in	IN	B-PP
B-Cancer	76	83	gastric	gastric	JJ	B-NP
I-Cancer	84	90	cancer	cancer	NN	I-NP
O	90	91	.	.	.	O

O	93	96	The	The	DT	B-NP
O	97	106	chemokine	chemokine	NN	I-NP
O	107	115	receptor	receptor	NN	I-NP
O	116	121	CXCR4	CXCR4	NN	I-NP
O	122	124	is	be	VBZ	B-VP
O	125	135	associated	associate	VBN	I-VP
O	136	140	with	with	IN	B-PP
O	141	144	the	the	DT	B-NP
O	145	155	biological	biological	JJ	I-NP
O	156	164	behavior	behavior	NN	I-NP
O	165	167	of	of	IN	B-PP
B-Cancer	168	174	cancer	cancer	NN	B-NP
O	174	175	,	,	,	O
O	176	179	but	but	CC	O
O	180	183	few	few	JJ	B-NP
O	184	191	studies	study	NNS	I-NP
O	192	196	have	have	VBP	B-VP
O	197	206	addressed	address	VBN	I-VP
O	207	210	the	the	DT	B-NP
O	211	221	expression	expression	NN	B-NP
O	222	225	and	and	CC	O
O	226	234	function	function	NN	B-NP
O	235	237	of	of	IN	B-PP
O	238	243	CXCR4	CXCR4	NN	B-NP
O	244	246	in	in	IN	B-PP
O	247	252	human	human	JJ	B-NP
B-Cancer	253	260	gastric	gastric	JJ	I-NP
I-Cancer	261	267	cancer	cancer	NN	I-NP
O	268	271	and	and	CC	O
O	272	275	its	its	PRP$	B-NP
O	276	282	impact	impact	NN	I-NP
O	283	285	on	on	IN	B-PP
O	286	293	disease	disease	NN	B-NP
O	294	303	prognosis	prognosis	NN	I-NP
O	303	304	.	.	.	O

O	305	307	We	We	PRP	B-NP
O	308	315	studied	study	VBD	B-VP
O	316	319	the	the	DT	B-NP
O	320	330	expression	expression	NN	I-NP
O	331	333	of	of	IN	B-PP
O	334	339	CXCR4	CXCR4	NN	B-NP
O	340	345	using	use	VBG	B-VP
O	346	348	RT	RT	NN	B-NP
O	348	349	-	-	HYPH	O
O	349	352	PCR	PCR	NN	B-NP
O	352	353	,	,	,	O
O	354	361	Western	Western	NN	B-NP
O	362	370	blotting	blotting	NN	I-NP
O	370	371	,	,	,	O
O	372	376	flow	flow	NN	B-NP
O	377	386	cytometry	cytometry	NN	I-NP
O	386	387	,	,	,	O
O	388	391	and	and	CC	O
O	392	400	confocal	confocal	JJ	B-NP
O	401	411	microscopy	microscopy	NN	I-NP
O	412	414	in	in	IN	B-PP
O	415	419	five	five	CD	B-NP
B-Cell	420	427	gastric	gastric	JJ	I-NP
I-Cell	428	434	cancer	cancer	NN	I-NP
I-Cell	435	439	cell	cell	NN	I-NP
I-Cell	440	445	lines	line	NNS	I-NP
O	445	446	.	.	.	O

O	447	449	We	We	PRP	B-NP
O	450	454	also	also	RB	B-ADVP
O	455	463	examined	examine	VBD	B-VP
B-Cell	464	468	cell	cell	NN	B-NP
O	469	482	proliferation	proliferation	NN	I-NP
O	482	483	,	,	,	O
O	484	493	migration	migration	NN	B-NP
O	493	494	,	,	,	O
O	495	498	and	and	CC	O
O	499	503	anti	anti	AFX	B-NP
O	503	504	-	-	HYPH	I-NP
O	504	513	apoptotic	apoptotic	JJ	I-NP
O	514	522	activity	activity	NN	I-NP
O	523	525	in	in	IN	B-PP
O	526	534	response	response	NN	B-NP
O	535	537	to	to	TO	B-PP
O	538	545	stromal	stromal	JJ	B-NP
O	546	550	cell	cell	NN	I-NP
O	550	551	-	-	HYPH	O
O	551	558	derived	derive	VBN	B-VP
O	559	565	factor	factor	NN	B-NP
O	566	567	(	(	(	O
O	567	570	SDF	SDF	NN	B-NP
O	570	571	)	)	)	O
O	571	572	-	-	HYPH	B-NP
O	572	578	1alpha	1alpha	NN	I-NP
O	579	582	and	and	CC	O
O	583	592	evaluated	evaluate	VBN	B-NP
O	593	596	SDF	SDF	NN	I-NP
O	596	597	-	-	HYPH	B-NP
O	597	603	1alpha	1alpha	NN	I-NP
O	603	604	/	/	SYM	I-NP
O	604	609	CXCR4	CXCR4	NN	I-NP
O	610	619	signaling	signaling	NN	I-NP
O	620	628	pathways	pathway	NNS	I-NP
O	628	629	.	.	.	O

O	630	641	Furthermore	Furthermore	RB	B-ADVP
O	641	642	,	,	,	O
O	643	645	we	we	PRP	B-NP
O	646	658	investigated	investigate	VBD	B-VP
O	659	662	the	the	DT	B-NP
O	663	674	correlation	correlation	NN	I-NP
O	675	682	between	between	IN	B-PP
O	683	688	CXCR4	CXCR4	NN	B-NP
O	689	699	expression	expression	NN	I-NP
O	700	703	and	and	CC	O
O	704	707	the	the	DT	B-NP
O	708	716	clinical	clinical	JJ	I-NP
O	717	725	features	feature	NNS	I-NP
O	726	728	of	of	IN	B-PP
O	729	732	221	221	CD	B-NP
B-Tissue	733	740	gastric	gastric	JJ	I-NP
I-Tissue	741	747	cancer	cancer	NN	I-NP
I-Tissue	748	754	tissue	tissue	NN	I-NP
I-Tissue	755	762	samples	sample	NNS	I-NP
O	762	763	.	.	.	O

O	764	769	CXCR4	CXCR4	NN	B-NP
O	770	781	transcripts	transcript	NNS	I-NP
O	782	785	and	and	CC	I-NP
O	786	794	proteins	protein	NNS	I-NP
O	795	799	were	be	VBD	B-VP
O	800	810	detectable	detectable	JJ	B-ADJP
O	811	813	in	in	IN	B-PP
O	814	817	all	all	DT	B-NP
O	818	822	five	five	CD	I-NP
B-Cell	823	830	gastric	gastric	JJ	I-NP
I-Cell	831	837	cancer	cancer	NN	I-NP
I-Cell	838	842	cell	cell	NN	I-NP
I-Cell	843	848	lines	line	NNS	I-NP
O	848	849	.	.	.	O

O	850	857	However	However	RB	B-ADVP
O	857	858	,	,	,	O
B-Cell	859	862	MKN	MKN	NN	B-NP
I-Cell	862	863	-	-	HYPH	O
I-Cell	863	865	28	28	CD	B-NP
O	865	866	,	,	,	O
B-Cell	867	870	MKN	MKN	NN	B-NP
I-Cell	870	871	-	-	HYPH	O
I-Cell	871	873	45	45	CD	B-NP
O	873	874	,	,	,	O
B-Cell	875	878	MKN	MKN	NN	B-NP
I-Cell	878	879	-	-	HYPH	O
I-Cell	879	881	74	74	CD	B-NP
O	881	882	,	,	,	O
O	883	886	and	and	CC	O
B-Cell	887	892	SNU16	SNU16	NN	B-NP
I-Cell	893	898	cells	cell	NNS	I-NP
O	899	902	did	do	VBD	B-VP
O	903	906	not	not	RB	I-VP
O	907	914	express	express	VB	I-VP
B-Cellular_component	915	923	membrane	membrane	NN	B-NP
O	924	929	CXCR4	CXCR4	NN	I-NP
O	929	930	.	.	.	O

O	931	933	In	In	IN	B-PP
O	934	942	contrast	contrast	NN	B-NP
O	942	943	,	,	,	O
B-Cell	944	948	KATO	KATO	NN	B-NP
I-Cell	949	952	III	III	CD	I-NP
I-Cell	953	958	cells	cell	NNS	I-NP
O	959	968	expressed	express	VBD	B-VP
B-Cellular_component	969	977	membrane	membrane	NN	B-NP
O	978	983	CXCR4	CXCR4	NN	I-NP
O	983	984	.	.	.	O

O	985	987	In	In	IN	B-PP
O	988	993	these	these	DT	B-NP
B-Cell	994	999	cells	cell	NNS	I-NP
O	999	1000	,	,	,	O
O	1001	1004	SDF	SDF	NN	B-NP
O	1004	1005	-	-	HYPH	B-NP
O	1005	1011	1alpha	1alpha	NN	I-NP
O	1011	1012	-	-	HYPH	B-NP
O	1012	1019	induced	induce	VBN	I-NP
O	1020	1029	migration	migration	NN	I-NP
O	1030	1033	was	be	VBD	B-VP
O	1034	1042	observed	observe	VBN	I-VP
O	1043	1046	and	and	CC	O
O	1047	1050	was	be	VBD	B-VP
O	1051	1058	blocked	block	VBN	I-VP
O	1059	1061	by	by	IN	B-PP
O	1062	1069	AMD3100	AMD3100	NN	B-NP
O	1069	1070	,	,	,	O
O	1071	1072	a	a	DT	B-NP
O	1073	1081	specific	specific	JJ	I-NP
O	1082	1091	inhibitor	inhibitor	NN	I-NP
O	1092	1094	of	of	IN	B-PP
O	1095	1100	CXCR4	CXCR4	NN	B-NP
O	1100	1101	.	.	.	O

O	1102	1105	SDF	SDF	NN	B-NP
O	1105	1106	-	-	HYPH	I-NP
O	1106	1112	1alpha	1alpha	NN	I-NP
O	1113	1120	induced	induce	VBD	B-VP
O	1121	1126	rapid	rapid	JJ	B-NP
O	1127	1142	phosphorylation	phosphorylation	NN	I-NP
O	1143	1145	of	of	IN	B-PP
O	1146	1150	Erk1	Erk1	NN	B-NP
O	1150	1151	/	/	SYM	O
O	1151	1152	2	2	CD	B-NP
O	1153	1157	MAPK	MAPK	NN	I-NP
O	1158	1161	but	but	CC	O
O	1162	1165	did	do	VBD	B-VP
O	1166	1169	not	not	RB	I-VP
O	1170	1177	promote	promote	VB	I-VP
O	1178	1193	phosphorylation	phosphorylation	NN	B-NP
O	1194	1196	of	of	IN	B-PP
O	1197	1202	Stat3	Stat3	NN	B-NP
O	1203	1205	or	or	CC	I-NP
O	1206	1209	Akt	Akt	NN	I-NP
O	1209	1210	.	.	.	O

B-Tissue	1211	1218	Gastric	Gastric	JJ	B-NP
I-Tissue	1219	1225	cancer	cancer	NN	I-NP
I-Tissue	1226	1232	tissue	tissue	NN	I-NP
I-Tissue	1233	1240	samples	sample	NNS	I-NP
O	1241	1250	expressed	express	VBD	B-VP
O	1251	1256	CXCR4	CXCR4	NN	B-NP
O	1257	1261	with	with	IN	B-PP
O	1262	1270	variable	variable	JJ	B-NP
O	1271	1282	intensities	intensity	NNS	I-NP
O	1282	1283	.	.	.	O

O	1284	1290	Strong	Strong	JJ	B-NP
O	1291	1296	CXCR4	CXCR4	NN	I-NP
O	1297	1307	expression	expression	NN	I-NP
O	1308	1311	was	be	VBD	B-VP
O	1312	1325	significantly	significantly	RB	I-VP
O	1326	1336	associated	associate	VBN	I-VP
O	1337	1341	with	with	IN	B-PP
B-Cancer	1342	1347	lymph	lymph	NN	B-NP
I-Cancer	1348	1352	node	node	NN	I-NP
I-Cancer	1353	1363	metastases	metastasis	NNS	I-NP
O	1364	1365	(	(	(	O
O	1365	1366	P	P	NN	B-NP
O	1366	1367	=	=	SYM	B-VP
O	1367	1368	0	0	CD	B-NP
O	1368	1369	.	.	SYM	I-NP
O	1369	1372	028	028	CD	I-NP
O	1372	1373	)	)	)	O
O	1374	1377	and	and	CC	O
O	1378	1384	higher	high	JJR	B-NP
O	1385	1391	stages	stage	NNS	I-NP
O	1392	1395	III	III	CD	B-NP
O	1395	1396	/	/	SYM	B-NP
O	1396	1398	IV	IV	CD	I-NP
O	1399	1400	(	(	(	O
O	1400	1401	P	P	NN	B-NP
O	1401	1402	=	=	SYM	B-VP
O	1402	1403	0	0	CD	B-NP
O	1403	1404	.	.	SYM	I-NP
O	1404	1407	047	047	CD	I-NP
O	1407	1408	)	)	)	O
O	1408	1409	,	,	,	O
O	1410	1413	and	and	CC	O
O	1414	1421	further	further	RB	B-VP
O	1422	1428	tended	tend	VBD	I-VP
O	1429	1431	to	to	TO	I-VP
O	1432	1434	be	be	VB	I-VP
O	1435	1445	correlated	correlate	VBN	I-VP
O	1446	1450	with	with	IN	B-PP
O	1451	1452	a	a	DT	B-NP
O	1453	1460	reduced	reduce	VBN	I-NP
O	1461	1462	5	5	CD	I-NP
O	1462	1463	-	-	HYPH	I-NP
O	1463	1467	year	year	NN	I-NP
O	1468	1476	survival	survival	NN	I-NP
O	1477	1481	rate	rate	NN	I-NP
O	1482	1483	(	(	(	O
O	1483	1485	42	42	CD	B-NP
O	1485	1486	.	.	.	O
O	1486	1487	6	6	CD	B-NP
O	1487	1488	%	%	NN	I-NP
O	1489	1491	vs	v	NNS	I-NP
O	1491	1492	.	.	.	O
O	1493	1495	53	53	CD	B-NP
O	1495	1496	.	.	.	O
O	1496	1497	9	9	CD	B-NP
O	1497	1498	%	%	NN	I-NP
O	1498	1499	;	;	:	O
O	1500	1501	P	P	NN	B-NP
O	1501	1502	=	=	SYM	B-VP
O	1502	1503	0	0	CD	B-NP
O	1503	1504	.	.	SYM	I-NP
O	1504	1505	1	1	CD	I-NP
O	1505	1506	)	)	)	O
O	1506	1507	.	.	.	O

O	1508	1510	In	In	IN	B-PP
O	1511	1521	conclusion	conclusion	NN	B-NP
O	1521	1522	,	,	,	O
O	1523	1528	CXCR4	CXCR4	NN	B-NP
O	1529	1539	expression	expression	NN	I-NP
O	1540	1542	is	be	VBZ	B-VP
O	1543	1553	associated	associate	VBN	I-VP
O	1554	1558	with	with	IN	B-PP
B-Cell	1559	1566	gastric	gastric	JJ	B-NP
I-Cell	1567	1573	cancer	cancer	NN	I-NP
I-Cell	1574	1578	cell	cell	NN	I-NP
O	1579	1588	migration	migration	NN	I-NP
O	1589	1591	in	in	FW	B-ADVP
O	1592	1597	vitro	vitro	FW	I-ADVP
O	1597	1598	,	,	,	O
O	1599	1602	and	and	CC	O
O	1603	1609	strong	strong	JJ	B-NP
O	1610	1620	expression	expression	NN	I-NP
O	1621	1623	of	of	IN	B-PP
O	1624	1629	CXCR4	CXCR4	NN	B-NP
O	1630	1632	by	by	IN	B-PP
B-Cell	1633	1640	gastric	gastric	JJ	B-NP
I-Cell	1641	1647	cancer	cancer	NN	I-NP
I-Cell	1648	1653	cells	cell	NNS	I-NP
O	1654	1656	is	be	VBZ	B-VP
O	1657	1670	significantly	significantly	RB	I-VP
O	1671	1681	associated	associate	VBN	I-VP
O	1682	1686	with	with	IN	B-PP
B-Organ	1687	1696	lymphatic	lymphatic	JJ	B-NP
O	1697	1707	metastasis	metastasis	NN	I-NP
O	1708	1710	in	in	IN	B-PP
O	1711	1719	patients	patient	NNS	B-NP
O	1720	1724	with	with	IN	B-PP
B-Cancer	1725	1732	gastric	gastric	JJ	B-NP
I-Cancer	1733	1739	cancer	cancer	NN	I-NP
O	1739	1740	,	,	,	O
O	1741	1751	suggesting	suggest	VBG	B-VP
O	1752	1756	that	that	IN	B-SBAR
O	1757	1762	CXCR4	CXCR4	NN	B-NP
O	1763	1768	plays	play	VBZ	B-VP
O	1769	1771	an	an	DT	B-NP
O	1772	1781	important	important	JJ	I-NP
O	1782	1786	role	role	NN	I-NP
O	1787	1793	during	during	IN	B-PP
B-Cancer	1794	1801	gastric	gastric	JJ	B-NP
I-Cancer	1802	1808	cancer	cancer	NN	I-NP
O	1809	1820	progression	progression	NN	I-NP
O	1820	1821	.	.	.	O

